Global Biosimilars Market Report and Forecast 2023-2031

Global Biosimilars Market Report and Forecast 2023-2031


Global Biosimilars Market Outlook


The biosimilars market size attained a value of USD 24.5 billion in 2022. The market is likely to grow at a CAGR of 17.60% during the forecast period of 2023-2031, likely to attain a value of USD 105.1 billion by 2031.

Biosimilars Market: Introduction and Application


Biosimilars are biological products that are highly similar to an already approved and marketed reference biologic drug, with no clinically meaningful differences in terms of safety, purity, and potency. They are derived from living organisms, such as bacteria, yeast, or mammalian cells, and are used to treat various diseases and medical conditions. Biosimilars are developed after the patent expiration of the original biologic drug, also known as the innovator product.

Biosimilars are used to treat a wide range of conditions, including autoimmune disorders (examples- rheumatoid arthritis and inflammatory bowel disease), cancer, diabetes, and blood disorders (examples- anaemia and neutropenia). They are used as therapeutic proteins, monoclonal antibodies, and hormones, among other applications.

The benefits of biosimilars include the following:
  • Cost Savings: As biosimilars are often less expensive than the reference biologic drugs, they can lead to substantial cost savings for healthcare systems and patients. This affordability increases patient access to essential medicines and treatments.
  • Competition: The introduction of biosimilars fosters market competition, which can drive down the prices of biologic drugs and improve their availability.
  • Innovation: Developing biosimilars requires extensive research and development, which can lead to the discovery of new therapeutic strategies and enhancements in biopharmaceutical manufacturing processes.
  • Expanding Treatment Options: The availability of biosimilars can provide healthcare professionals and patients with additional treatment options, leading to more personalized and effective care.

Biosimilars Market Segmentations


The market can be categorised into product type, drug type, indication, procedure, and region.

Market by Product Type
  • Recombinant Glycosylated Proteins
  • Monoclonal Antibodies
  • Erythropoietin
  • Recombinant Non-Glycosylated Proteins
  • Insulins
  • Granulocyte Colony Stimulating Factors
  • Interferons
  • Others
Market Breakup by Drug Class
  • Insulin
  • Recombinant Human Growth Hormone (RHGH)
  • Granulocyte Colony-Stimulating Factor
  • Interferon
  • Erythropoietin
  • Etanercept
  • Monoclonal Antibodies
  • Follitropin
  • Glucagon
  • Calcitonin
  • Teriparatide
  • Enoxaparin Sodium
  • Others
Market Breakup by Indications
  • Chronic Diseases
  • Oncology
  • Autoimmune Diseases
  • Infectious Diseases
  • Blood Disorders
  • Growth Hormone Deficiency
  • Others
Market Breakup by Procedure
  • Invasive
  • Non-Invasive
  • Biosimilars Market Breakup by Region
  • North America
  • United States of America
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Biosimilars Market Scenario


The global biosimilars market has been witnessing rapid growth, driven by factors such as patent expiration of blockbuster biologic drugs, increasing prevalence of chronic diseases, and rising demand for cost-effective treatment options. Regulatory support and streamlined approval pathways have facilitated the entry of biosimilars into the market, leading to increased competition and more affordable healthcare options.

In addition, the growing awareness of biosimilars among healthcare professionals and patients has further fuelled market expansion. Emerging markets, such as those in Asia Pacific and Latin America, offer significant growth potential due to their large patient populations and improving healthcare infrastructure. Key industry players are focusing on strategic partnerships, collaborations, and mergers and acquisitions to strengthen their product pipelines, expand their global presence, and capitalize on the growing market opportunities. Overall, the biosimilars market scenario presents a promising outlook, with the potential to significantly improve patient access to life-changing therapies and alleviate the financial burden on healthcare systems worldwide.

Key Players in the Global Biosimilars Market


The report gives an in-depth analysis of the key players involved in the biosimilars market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Novartis AG
  • Orion Pharma
  • Pfizer Inc.
  • Samsung Bioepis
  • Coherus BioSciences, Inc.
  • Amgen Inc.
  • Eli Lilly and Company.
  • Takeda Pharmaceutical Company Limited.
  • Bristol-Myers Squibb Company
  • Merck KGaA
  • Teva Pharmaceutical Industries Ltd.
  • Biocon
  • Bayer AG
  • AbbVie Inc,
  • Allergan
  • Dr. Reddy’s Laboratories Ltd.
  • Boehringer Ingelheim International GmbH.
  • Biogen
*Please Note:* The report will be completed in 7 business days after order confirmation


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Biosimilars Market Overview
3.1 Global Biosimilars Market Historical Value (2016-2022)
3.2 Global Biosimilars Market Forecast Value (2023-2031)
4 Global Biosimilars Market Landscape
4.1 Global Biosimilars Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Biosimilars Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Drug Class
4.2.3 Analysis by Procedure
5 Global Biosimilars Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Biosimilars Market Segmentation
6.1 Global Biosimilars Market by Product Type
6.1.1 Recombinant Glycosylated Proteins
6.1.1.1 Monoclonal Antibodies
6.1.1.2 Erythropoietin
6.1.2 Recombinant Non-Glycosylated Proteins
6.1.2.1 Insulins
6.1.2.2 Granulocyte Colony Stimulating Factors
6.1.2.3 Interferons
6.1.2.4 Others
6.2 Global Biosimilars Market by Drug Class
6.2.1 Market Overview
6.2.2 Insulin
6.2.3 Recombinant Human Growth Hormone (RHGH)
6.2.4 Granulocyte Colony-Stimulating Factor
6.2.5 Interferon
6.2.6 Erythropoietin
6.2.7 Etanercept
6.2.8 Monoclonal Antibodies
6.2.9 Follitropin
6.2.10 Glucagon
6.2.11 Calcitonin
6.2.12 Teriparatide
6.2.13 Enoxaparin Sodium
6.2.14 Others
6.3 Global Biosimilars Market by Indications
6.3.1 Market Overview
6.3.2 Chronic Diseases
6.3.3 Oncology
6.3.4 Autoimmune Diseases
6.3.5 Infectious Diseases
6.3.6 Blood Disorders
6.3.7 Growth Hormone Deficiency
6.3.8 Others
6.4 Global Biosimilars Market by Procedure
6.4.1 Market Overview
6.4.2 Invasive
6.4.3 Non-Invasive
6.5 Global Biosimilars Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Biosimilars Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Biosimilars Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Biosimilars Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Biosimilars Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Biosimilars Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Novartis AG
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Orion Pharma
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Pfizer Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Samsung Bioepis
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Coherus BioSciences, Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Amgen Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Eli Lilly and Company.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Takeda Pharmaceutical Company Limited.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Bristol-Myers Squibb Company
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Merck KGaA
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Teva Pharmaceutical Industries Ltd.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Biocon
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Bayer AG
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 AbbVie Inc,
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Allergan
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
17.16 Dr. Reddy’s Laboratories Ltd.
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisitions
17.16.5 Certifications
17.17 Boehringer Ingelheim International GmbH.
17.17.1 Financial Analysis
17.17.2 Product Portfolio
17.17.3 Demographic Reach and Achievements
17.17.4 Mergers and Acquisitions
17.17.5 Certifications
17.18 Biogen
17.18.1 Financial Analysis
17.18.2 Product Portfolio
17.18.3 Demographic Reach and Achievements
17.18.4 Mergers and Acquisitions
17.18.5 Certifications
18 Global Biosimilars Market- Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings